• Something wrong with this record ?

Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network

M. Pallauf, S. Brönimann, ME. Rezaee, TP. Kohn, SA. Fletcher, M. McNamara, D. Enikeev, SF. Shariat, J. Hoffman-Censits, AK. Smith, N. Singla

. 2025 ; 43 (7) : 441.e11-441.e18. [pub] 20250122

Language English Country United States

Document type Journal Article, Comparative Study, Research Support, Non-U.S. Gov't

PURPOSE: To investigate the association of diabetes mellitus and metformin use with metabolic acidosis risk after radical cystectomy (RC) and urinary diversion for bladder cancer. MATERIALS AND METHODS: This retrospective cohort study used TriNetX Research Network data. Patients undergoing RC with continent diversion or ileal conduit for bladder cancer were identified using International Classification of Diseases, 10th Revision (ICD-10) and ICD-10 Procedure Coding System (ICD-10-PCS) codes. The primary outcome was acidosis between 1 month and 3 years postsurgery. Risk ratios (RR) and odds ratios (OR) were calculated based on diabetes and metformin use, stratified by diversion type and chronic kidney disease stage. Propensity score matching balanced potential confounders. RESULTS: We identified 1,986 patients who underwent continent diversion and 11,184 who underwent ileal conduit reconstruction. In matched analyses, diabetes patients had higher acidosis risk (continent diversion: RR 1.87, 95% confidence interval [CI] 1.39-2.51; ileal conduit: RR 1.94, 95% CI 1.66-2.27). The risk was highest for diabetes patients with metformin prescription (continent diversion: RR 2.06, 95% CI 1.63-2.61; ileal conduit: RR 2.13, 95% CI 1.84-2.47). However, among patients with diabetes, metformin use did not significantly affect acidosis rates in most analyses. Continent diversion patients had higher acidosis risk than ileal conduit patients (RR 1.89, 95% CI 1.58-2.26). CONCLUSION: Diabetes significantly increases metabolic acidosis risk after RC with urinary diversion, especially in continent diversion patients. While metformin may contribute to metabolic acidosis risk, its impact appears less significant than that of diabetes. Careful monitoring and appropriate metformin adjustments are crucial in this population.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015226
003      
CZ-PrNML
005      
20250731090839.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2024.12.275 $2 doi
035    __
$a (PubMed)39848843
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pallauf, Maximilian $u Department of Urology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria; The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
245    10
$a Metformin intake and risk of metabolic acidosis after radical cystectomy with urinary diversion: A comparative study using data from the TriNetX research network / $c M. Pallauf, S. Brönimann, ME. Rezaee, TP. Kohn, SA. Fletcher, M. McNamara, D. Enikeev, SF. Shariat, J. Hoffman-Censits, AK. Smith, N. Singla
520    9_
$a PURPOSE: To investigate the association of diabetes mellitus and metformin use with metabolic acidosis risk after radical cystectomy (RC) and urinary diversion for bladder cancer. MATERIALS AND METHODS: This retrospective cohort study used TriNetX Research Network data. Patients undergoing RC with continent diversion or ileal conduit for bladder cancer were identified using International Classification of Diseases, 10th Revision (ICD-10) and ICD-10 Procedure Coding System (ICD-10-PCS) codes. The primary outcome was acidosis between 1 month and 3 years postsurgery. Risk ratios (RR) and odds ratios (OR) were calculated based on diabetes and metformin use, stratified by diversion type and chronic kidney disease stage. Propensity score matching balanced potential confounders. RESULTS: We identified 1,986 patients who underwent continent diversion and 11,184 who underwent ileal conduit reconstruction. In matched analyses, diabetes patients had higher acidosis risk (continent diversion: RR 1.87, 95% confidence interval [CI] 1.39-2.51; ileal conduit: RR 1.94, 95% CI 1.66-2.27). The risk was highest for diabetes patients with metformin prescription (continent diversion: RR 2.06, 95% CI 1.63-2.61; ileal conduit: RR 2.13, 95% CI 1.84-2.47). However, among patients with diabetes, metformin use did not significantly affect acidosis rates in most analyses. Continent diversion patients had higher acidosis risk than ileal conduit patients (RR 1.89, 95% CI 1.58-2.26). CONCLUSION: Diabetes significantly increases metabolic acidosis risk after RC with urinary diversion, especially in continent diversion patients. While metformin may contribute to metabolic acidosis risk, its impact appears less significant than that of diabetes. Careful monitoring and appropriate metformin adjustments are crucial in this population.
650    _2
$a lidé $7 D006801
650    12
$a metformin $x škodlivé účinky $x terapeutické užití $7 D008687
650    12
$a diverze moči $x škodlivé účinky $x metody $7 D014547
650    12
$a cystektomie $x škodlivé účinky $x metody $7 D015653
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a acidóza $x etiologie $x epidemiologie $x chemicky indukované $7 D000138
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a senioři $7 D000368
650    12
$a nádory močového měchýře $x chirurgie $7 D001749
650    _2
$a lidé středního věku $7 D008875
650    12
$a hypoglykemika $x škodlivé účinky $x terapeutické užití $7 D007004
650    12
$a pooperační komplikace $x etiologie $7 D011183
655    _2
$a časopisecké články $7 D016428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brönimann, Stephan $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
700    1_
$a Rezaee, Michael E $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
700    1_
$a Kohn, Taylor P $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
700    1_
$a Fletcher, Sean A $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD
700    1_
$a McNamara, Meghan $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins Urologic Oncology at Sibley Memorial Hospital, Washington, DC
700    1_
$a Enikeev, Dmitry $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medicine, Tel Aviv University, Israel; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; Research Center for Evidence Medicine, Urology Department Tabriz University of Medical Sciences, Tabriz, Iran
700    1_
$a Hoffman-Censits, Jean $u Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
700    1_
$a Smith, Armine K $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Johns Hopkins Urologic Oncology at Sibley Memorial Hospital, Washington, DC
700    1_
$a Singla, Nirmish $u The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: nsingla2@jhmi.edu
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 43, č. 7 (2025), s. 441.e11-441.e18
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39848843 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090834 $b ABA008
999    __
$a ok $b bmc $g 2366215 $s 1252351
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 43 $c 7 $d 441.e11-441.e18 $e 20250122 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...